BIOGEN INC.
Nasdaq: BIIB·Cambridge, Massachusetts·CIK 0000875045
- Price
- $251.65
- Base IV
- $187.71
Valuation snapshot
At $251.65, the price sits between our base case ($187.71) and bull case ($388.87).
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $187.71
- 75% of the price · range $62.02–$388.87
- Price vs base case
- 34% above
- $251.65 against $187.71
- Base case · our researched forecast, 2026-10-29See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
Whisker on the base case runs bear $62.02 to bull $388.87. Values per share.
Price against each value
- Bear case
- $62.02
- Price 306% above
- No growth
- …
- —
- Base case
- $187.71
- Price 34% above
What does Biogen do?
Biogen develops and commercializes medicines and biosimilars to treat neurological disorders, rare diseases, and immune system conditions such as multiple sclerosis and spinal muscular atrophy.
It brought in $10.3B of sales in the 12 months to Sep 2026.
Led by Christopher A. Viehbacher, President and Chief Executive Officer since 2022. Biogen Names Christopher A. Viehbacher President and Chief Executive Officer
- Industry
- Healthcare
- Based in
- Cambridge, Massachusetts
- Trades on
- Nasdaq as BIIB
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 3¢ was left as profit after every cost, interest and tax. The biggest cost is sales, marketing and admin, 27¢ of every dollar.
- Making what it sells26¢
- Research and development21¢
- Sales, marketing and admin27¢
- Everything else, including interest22¢
- Tax1¢
- Left as profit3¢
Who pays Biogen, and for what?
Biogen develops and sells medicines for serious diseases, with a focus on neurology, specialized immunology and rare diseases. It earns revenue from its own drug sales and biosimilars, plus financial rights and collaboration revenue from medicines developed or marketed with other companies.
Patients use its medicines, while healthcare providers, pharmacies, distributors, insurers and government health programs help purchase, prescribe or pay for them.
Multiple sclerosis products
41%Medicines including TYSABRI, VUMERITY, TECFIDERA, AVONEX and PLEGRIDY.
Rare disease products
22%Medicines including SPINRAZA, SKYCLARYS and QALSODY.
Anti-CD20 therapeutic programs
19%Financial rights from programs including OCREVUS, RITUXAN, GAZYVA and others marketed by Roche and its partners.
Biosimilars
7%Similar versions of established biologic medicines, including BENEPALI, IMRALDI and FLIXABI.
Alzheimer's collaboration
2%Biogen's share of LEQEMBI revenue and related costs under its collaboration with Eisai.
LEQEMBI dosing optionsImage: Eisai Other product and contract revenue
9%Other medicines, manufacturing, royalties and related revenue.
Where its work physically happens, beyond headquarters:
- Research Triangle Park manufacturing campus — Research Triangle Park, United States. Biogen’s largest manufacturing footprint produces AVONEX, PLEGRIDY, TYSABRI and QALSODY and includes capacity for clinical and commercial oligonucleotide therapies.
- Solothurn biologics facility — Solothurn, Switzerland. This large-scale biologics facility manufactures LEQEMBI and TYSABRI and expands Biogen’s capacity for its product portfolio.
- Athlone fill-finish facility — Athlone, Ireland. Acquired in 2025, the facility is intended to add sterile syringe and cartridge filling capacity for Biogen’s multiple sclerosis products and late-stage pipeline.
- Cambridge research laboratory — Cambridge, United States. This separately listed, company-owned research laboratory supports Biogen’s drug-discovery work.
- Baar international headquarters — Baar, Switzerland. Biogen’s international team coordinates strategic and operational activity across Europe, Canada, Latin America, the Middle East and Asia Pacific from this office.
How is the business doing?
Sales shrank from $13.4B in 2020 to $9.9B in 2025, about 6% a year.
Running the business leaves about 26¢ of each sales dollar as operating profit, down from 34¢ in 2020.
After paying for its upkeep and new investment, it had $2.1B of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
Biogen says it aims to use science to develop medicines that improve patients' lives and create value for its shareholders and communities.
“Pioneers innovative science to deliver new medicines to transform patients’ lives”
Who is responsible for the plan?
- Christopher A. ViehbacherPresident and Chief Executive Officer
Oversees Biogen's global business operations, corporate strategy, and organizational governance. Biogen discovers, develops, and delivers therapies for serious neurological and rare diseases to generate biopharmaceutical revenues.
- Rachid IzzarExecutive Vice President, Head of Global Product Strategy & Commercialization
Oversees global commercial operations, product marketing strategy, and market access across Biogen's therapeutic portfolio. Commercialization strategy and market access drive worldwide sales and distribution of Biogen's biopharmaceutical products.
- Priya Singhal, M.D., M.P.H.Executive Vice President, Head of Development
Oversees global clinical development programs, regulatory sciences, and pipeline advancement across Biogen's portfolio. Clinical development and regulatory approvals advance investigational candidates to commercialized therapies that generate revenue.
Roles checked November 14, 2026.
What management says it is working on now:
Grow newer medicines
Management says it expects growth from its newer products, including continued launches of SKYCLARYS and QALSODY in international markets.
Biogen Q2 2026 results and guidanceAdvance research and development
The company is advancing research in neurology, specialized immunology and rare diseases, using internal programs and outside collaborations.
Biogen Inc. 2025 Form 10-KExpand commercial launches
Biogen increased sales and marketing activity to support LEQEMBI and SKYCLARYS launches in the U.S. and international markets.
Biogen Inc. 2025 Form 10-KImprove operating efficiency
The Fit for Growth program and portfolio prioritization are intended to reduce costs and direct resources toward selected opportunities.
Biogen Inc. 2025 Form 10-KSupport reliable supply
Biogen is investing in manufacturing capacity and facilities to supply current medicines and support its development pipeline.
Biogen Inc. 2025 Form 10-K
- 2026 total revenue, 2026
- Increase by a mid-single-digit percentage year over year
- Biogen Q2 2026 results and guidance
- 2026 non-GAAP diluted earnings per share, 2026
- $12.00 to $13.00
- Updated guidance reflects a strong business outlook and investment for growth
- Second-half 2026 non-GAAP research and development and selling, general and administrative expenses, Second half of 2026
- $2.65 billion to $2.70 billion combined
- Biogen Q2 2026 results and guidance
- 2026 non-GAAP tax rate, 2026
- 17.5% to 18.5%
- Updated guidance reflects a strong business outlook and investment for growth
What's changing right now?
Growth is picking up. In Q3 2026 it sold 11% more than a year earlier. The year before, quarters averaged 0%.
The share price is about where it was in Oct 2026, near $251.65.
Recently
September 30, 2026
Multiple sclerosis revenue, third quarter changed to $919.0M
Biogen Q3 2026 results
Coming up
May 24, 2026 (PDUFA action date stated in the 10-K)
FDA decision on LEQEMBI weekly starting-dose autoinjector
The FDA accepted the supplemental application for review; the decision could affect how the medicine is started and delivered.
Biogen Inc. 2025 Form 10-KApril 3, 2026 (PDUFA action date stated in the 10-K)
FDA decision on higher-dose SPINRAZA regimen
Biogen resubmitted its application after the FDA requested technical manufacturing information; the filing reported an action date for the resubmission.
Biogen Inc. 2025 Form 10-K2026
Expected start of salanersen Phase 3 study
Biogen said it expects to begin a Phase 3 study of this investigational SMA medicine.
Biogen Inc. 2025 Form 10-KOngoing; no results date stated
Phase 3 EMPEROR study of zorevunersen
The global study of this investigational Dravet syndrome medicine began enrolling patients; future trial results could affect its development path.
Biogen Inc. 2025 Form 10-K
Our own estimate moved too: the base case went from $185.52 to $187.71 a share between our last two valuations.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Competition and loss of exclusivity
New treatments, generics and biosimilars can reduce prices and sales. Generic versions have already cut TECFIDERA revenue, and Biogen expects further declines; a TYSABRI biosimilar also pressures sales.
From the company's own filingsWould hit how fast sales growBiogen Inc. 2025 Form 10-K
Drug pricing and reimbursement
Government programs and insurers can limit coverage or lower payment for medicines. New laws or pricing policies could further reduce sales or make it harder for patients to access treatments.
From the company's own filingsWould hit how fast sales growBiogen Inc. 2025 Form 10-K
Clinical and regulatory uncertainty
Many drug candidates fail in testing or may be delayed, restricted or rejected by regulators, even after earlier promising results. That could limit future products and the return on research spending.
From the company's own filingsWould hit how fast sales growBiogen Inc. 2025 Form 10-K
Reliance on collaborators
Biogen depends on partners for revenue, development, approvals or sales of some medicines. Disagreements or a partner's changed priorities or performance could delay programs or reduce revenue.
From the company's own filingsWould hit how fast sales growBiogen Inc. 2025 Form 10-K
Product concentration and launch execution
A substantial portion of revenue comes from a limited set of products and programs. New launches such as LEQEMBI and SKYCLARYS may not gain expected coverage, use or acceptance.
From the company's own filingsWould hit how fast sales growBiogen Inc. 2025 Form 10-K
Manufacturing and supply disruptions
Biogen relies on some overseas partners and suppliers for ingredients and processes. Trade restrictions, tariffs or difficulty qualifying replacements could increase costs or interrupt supply.
From the company's own filingsWould hit how much of each sale it keepsBiogen Inc. 2025 Form 10-K
Q3 2026 multiple sclerosis revenue fell 0.13 and biosimilars revenue fell 0.16 year over year.
From our researchWould hit how fast sales growBiogen Q3 2026 results
The $5,071.1 million cash outlay for Apellis shows how much investment growth through acquisitions can require.
From our researchWould hit how much it has to reinvestBiogen Q3 2026 Form 10-Q
Is it a good business?
From 2016 to 2021 it earned between 14% and 43% on the capital invested in it, a median of 30%. Its cost of capital in the latest valuation is 6.3%; returns were above it in every one of the 6 years.
From 2016 to 2025 it earned between 7% and 44% on its shareholders' equity, a median of 21%.
Over 6 years its operating margin ranged from 26¢ to 49¢ per sales dollar, a median of 44¢. Gross margin ran from 74¢ to 87¢.
It bought back shares: the count fell 29% from 2016 to 2020, so each remaining share owns a bigger slice.
It owes $6B more than it holds in cash. An operating-profit comparison is unavailable from the published quarters.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $251.65. Our put its value between $62.02 and $388.87, with $187.71 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $62.02
Although Biogen's sales recently returned to growth, this case assumes older medicines lose customers fast enough to leave sales nearly flat and keep profits under pressure.
Base case, $187.71
After sales returned to growth in 2025 and rose faster in the latest quarter, this case assumes newer medicines keep the business growing moderately while older ones fade.
Bull case, $388.87
With sales rising again and newer medicines growing quickly, this case assumes successful launches keep lifting sales and let Biogen earn more from each dollar it brings in.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects more than we do.Price above value: 34%
For Biogen to be worth today's $251.65, sales would need to grow about 9.8% a year. We assume 4.0%. Over the last 5 years, sales shrank 1.5% a year.
Or, if sales grow 4.0% as we assume, the price works with a profit margin of 32.0% (we assume 25.0%).
Keep in mind: this is one way to read the price. Investors might be expecting other things, like higher profits or lower risk.
Do you think sales can grow 9.8% a year?
Try your own numbersWe're not very sure of this range: it scores 42 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $187.71 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average4.0%
- Operating margin25.0%
- Long-term growth rate1.5%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$187.71 -25.4%

